A
Arthur M. Feldman
Researcher at Thomas Jefferson University
Publications - 296
Citations - 41891
Arthur M. Feldman is an academic researcher from Thomas Jefferson University. The author has contributed to research in topics: Heart failure & Tumor necrosis factor alpha. The author has an hindex of 79, co-authored 289 publications receiving 40355 citations. Previous affiliations of Arthur M. Feldman include Johns Hopkins University School of Medicine & Valley Hospital.
Papers
More filters
Journal ArticleDOI
Adenosine Inhibits Lipopolysaccharide-Induced Cardiac Expression of Tumor Necrosis Factor-α
Daniel R. Wagner,Alain Combes,Charles F. McTiernan,Virginia J. Sanders,Bonnie Lemster,Arthur M. Feldman +5 more
TL;DR: It is demonstrated that adenosine can significantly diminish TNF-alpha levels in the heart, and the effect appears to be mediated by the A2 receptor and transduced through a G protein-adenylyl cyclase pathway.
Journal ArticleDOI
Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Effect of Aldosterone Antagonism With Eplerenone on Ventricular Remodeling in Patients With Mild-to-Moderate Heart Failure and Left Ventricular Systolic Dysfunction
James E. Udelson,Arthur M. Feldman,Barry H. Greenberg,Bertram Pitt,Robin Mukherjee,Henry Solomon,Marvin A. Konstam +6 more
TL;DR: In a clinically stable, well-treated population of patients with mild-to-moderate HF symptoms and LV dysfunction, 36 weeks of treatment of aldosterone antagonism with eplerenone at a dose of 50 mg daily had no detectable effect on parameters of LV remodeling.
Journal ArticleDOI
Overexpression of tumor necrosis factor- alpha activates both anti- and pro-apoptotic pathways in the myocardium.
Toru Kubota,Masayuki Miyagishima,Carole S. Frye,Sean Alber,George S. Bounoutas,Toshiaki Kadokami,Simon C. Watkins,Charles F. McTiernan,Arthur M. Feldman +8 more
TL;DR: The results suggest that TNF- α by itself is not sufficient to induce apoptosis in cardiac myocytes in vivo, and signaling pathways responsible for T NF-α induced apoptosis should be elucidated.
Journal ArticleDOI
Consensus recommendations for the management of chronic heart failure: Introduction
Milton Packer,Jay N. Cohn,William T. Abraham,Wilson S. Colucci,Michael B. Fowler,Barry H. Greenberg,Carl V. Leier,Barry M. Massie,James B. Young,Keith D. Aaronson,Jonathan Abrams,Kirkwood F. Adams,Joseph S. Alpert,Inder S. Anand,Paul W. Armstrong,David W. Baker,Alan J. Bank,George A. Beller,Jeffrey S. Borer,Robert C. Bourge,John C. Burnett,Blase A. Carabello,Peter E. Carson,Kanu Chatterjee,Guillermo Cintron,Robert J. Cody,C. Richard Conti,Maria Rosa Costanzo,Mark A. Creager,Charles L. Curry,G. William Dec,Prakash Deedwania,Louis J. Dell'Italia,Eduardo de Marchena,Teresa De Marco,Anthony N. DeMaria,Robert DiBianco,Thomas J. Donohue,Paul Douglass,W. Bruce Dunkman,Uri Elkayam,Rodney H. Falk,Arthur M. Feldman,Keith C. Ferdinand,Ross D. Fletcher,Gregg C. Fonarow,Joseph A. Franciosa,Gary S. Francis,Robert P. Frantz,William H. Gaasch,Edward M. Geltman,Mihai Gheorghiade,Edward M. Gilbert,Thomas D. Giles,Michael M. Givertz,Steven A. Goldman,Steven R. Goldsmith,Sidney Goldstein,Stephen S. Gottlieb,Alan H. Gradman,John Gregory,Ernie Haeusslein,Joe L. Hargrove,Denise D. Hermann,Ray E. Hershberger,J. Thomas Heywood,Michael B. Higginbotham,James A. Hill,William B. Hood,Jeffrey D. Hosenpud,Syed A.Q. Jafri,Frank James,Mariell Jessup,Thomas S. Johnston,Bodh I. Jugdutt,Frederic R. Kahl,Niki E. Kantrowitz,Edward K. Kasper,Arnold M. Katz,Richard J. Katz,Stuart D. Katz,Philip C. Kirlin,Robert M. Kohn,Marvin A. Konstam,John B. Kostis,Peter R. Kowey,Steven K. Krueger,Marrick L. Kukin,Andrew G. Kumpuris,Thierry H. Le Jemtel,Forrester A. Lee,T. Barry Levine,Chang Seng Liang,Henry S. Loeb,Evan Loh,Beverly H. Lorell,Jerre F. Lutz,George I. Mallis,Donna Mancini +98 more
Journal ArticleDOI
The International EECP Patient Registry (IEPR): design, methods, baseline characteristics, and acute results.
Gregory W. Barsness,Arthur M. Feldman,David R. Holmes,Richard Holubkov,Sheryl F. Kelsey,Elizabeth D. Kennard +5 more
TL;DR: The Registry population comprises all patients starting EECP therapy for treatment of angina pectoris in participating centers, and it is concluded that the number of patients in the Registry is likely to increase over the course of the treatment period.